"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"

Raymond Chow has recently stepped in as the Vice President, Asia Pacific at USheadquartered Cytiva, a global provider of technologies and services for biological therapies, formerly known as GE Healthcare Life Sciences.

- Ankit Kankar

Chow brings with him more than 30 years’ experience in the life sciences industry, working with renowned companies such as Philips Healthcare, Boston Scientific, GE Healthcare, BD. In conversation with BioSpectrum Asia, Raymond Chow, Vice President- Asia Pacific, Cytiva shares details about his vision to take the brand to the next level. 

What are the key drivers for you to join Cytiva? What “new air” do you hope to bring to Cytiva?

One of the major factors in my decision to join Cytiva was the allure of the biotech/biopharma sector, where so many technologies are being developed to address the need for new therapeutics that can serve the community at large. The merger of Pall Life Sciences and Cytiva forming the “new Cytiva” also possesses the portfolio and technical expertise that can address the needs of the industry to bring these therapeutics from bench to bedside. This is what excites me. As an experienced business veteran, I am also curious to apply the Danaher Business System (DBS) to create an environment where our people can bring their best to work, and help our customers bring lifechanging therapeutics to the wider community in the shortest time possible.

After the integration of Cytiva and Pall Life Sciences, what are the key strengths and challenges for the “new” company?